Objective: The present study empirically examines, in real-life practise and using multiple proxies, the impact of health care expenditures on overall survival in locally advanced and metastatic NSCLC in order to guide medical decision-making.
INTRODUCTION
At the macro-level, increased health care expenditure implies increased benefits for the patients (Cremieux et al., [1999] ). However, this has not yet proven true at the micro-level.
Since the demonstration by Cochrane et al. that indicators of health care inputs are generally not associated with outcomes (Cochrane et al., [1978] ), the failure to identify a relationship between health care expenditure and health outcomes has become a persistent theme in the literature. Socioeconomic factors are recognized to be highly associated with health outcomes (Nolte and Mc Kee, [2004] ; Young, [2001] ; Saint Leger, [2001] ). Lichtenberg has shown that cancers for which the stock of drugs increases more rapidly tend to have greater increases in survival rates, and the development of new cancer drugs generally increases the life expectancy of people diagnosed with cancer (Lichtenberg, [2004] ). Martin et al. have shown that health care expenditure has a strong positive effect on outcomes (Martin et al., [2007] ).
They have found that a one percent increase in expenditure per head induces, ceteris paribus, a 0.38% reduction in years of life lost from cancer.
The present study focuses on the "real life" situations (as opposed to clinical trials) of patients with advanced or metastatic Non Small Cell Lung Cancer (NSCLC). NSCLC accounts for approximately 85% of all lung cancer cases, mostly late stage diseases with poor survival prognosis (Cella et al., [2000] ; Burdett et al., [2008] ).
Indeed, patients with locally advanced NSCLC are not candidates for surgery, their median survival is less than one year (Galetta et al., [2002] ), and their 5-year survival rate is less than 5%. The modest survival rates, high toxicities, and high costs of treatment due to multiple chemotherapy regimens have prompted investigators to examine the potential benefits of new drugs. Clinical trials generally show that chemotherapy can improve survival, as compared to best supportive care, in stage IIIB and IV NSCLC (Hensing et al., [1999] ; Thongprasert et al., [1999] ; Cullen et al., [1999] ; Burdett et al., [2008] ; Berhoune et al., [2008] ). Economic studies have also shown that chemotherapy drugs are generally cost effective, as compared to best supportive care (Carlson et al., [2008] ). However, increasing the number of chemotherapy prescriptions, prolonging cytotoxic therapy, and using innovative and expensive chemotherapy drugs do not seem to improve overall survival (Socinsky et al., [2003] ; Pujol et al., [2005] ; Rubio-Terrés et al., [2002] ; Burdett et al., [2008] ; Gridelli et al., [2007] ).
In this context, and with the objective of guiding medical decision-making, we conducted a real-life practice study, based on retrospective data, to analyze the effects of health care expenditures on survival for patients with advanced NSCLC.
MATERIAL AND METHODS

Inclusion and exclusion criteria
All patients with stage IIIB or IV NSCLC treated with chemotherapy at the regional cancer centre of Lyon, France, between January 1, 2000 and December 31, 2004 were included in the study. Patients starting chemotherapy in another hospital, those receiving radiosensitizing chemotherapy alone, and those with stage I, II, or IIIA NSCLC were excluded from the study.
Data source
All data related to the characteristics of the patients and the resources used ( , , , , ) were extracted from patient records kept by the Cancer Centre. The costs of irradiation sessions ( ) were obtained from the "Classification Commune des Actes
Médicaux" (CCAM), the costs of hospitalisation ( ) were calculated by the accounting We collected data on patient age and sex, smoking habits, performance status (PS), significant weight loss (10% of total body weight or more), as well as disease stage (IIIB versus IV) and histology (adenocarcinoma versus epidermoid or malpighian carcinoma versus large cell carcinoma). Past or concomitant cardiovascular disease and/or diabetes were also noted.
Health outcomes
The indicator used to evaluate treatment efficacy was overall survival from the date of diagnosis.
Cost evaluation
Costs were calculated from the hospital's point of view. Survival time was calculated from the date of diagnosis until the date of death or the date of the last follow-up when patients were still alive (survival time was in this case therefore censored). Univariate survival analyses were performed by calculating Kaplan-Meier estimates. Differences between survival distributions were tested using log-rank statistics.
Multivariate analyses
Several expenditure indicators (logarithm of the total cost of treatment per day of hospitalisation, , number of chemotherapy drugs administered, inpatient length of stay), and survival data were modelled using multiple regression analyses. Since health care spendings and survival were jointly determined, expenditures were predictive of survival and conversely. Due to this bi-directional relationship, we could suspect a risk of endogeneity (Gujarati, [2005] ; Greene, [2003] ). Without any control for endogeneity, estimates from a standard Cox proportional hazard model for survival on the one hand, and from Ordinary Least Squares (OLS) for health expenditures models on the other hand, could be biased and inconsistent. Therefore we controlled endogeneity using the instrumental variable approach.
The choice of the appropriate instrument(s) was based on data from the medical literature, practising oncologists' expertise and on our intermediate results. For all analyses, statistical significance was set at 5%. Calculations were performed using Stata 10.0 software.
RESULTS
Descriptive statistics
Characteristics of patients
Main patient characteristics are described in table I. The sample consisted of a cohort of 175 patients of whom 73% were male. Mean age at inclusion was 60 years. A vast majority of patients (79%) had stage IV tumours. Adenocarcinoma was the main histological group (47% of the patients), followed by epidermoid or malpighian carcinoma (23%), and large cell carcinoma (30%). In total, 124 patients were current or former smokers (71%), 21 (12%) had concomitant or past cardiovascular disease and/or diabetes, and 35 (20%) reported significant weight loss. The prevalence of poor performance status was high (63% of the patients), with 37% of the patients scoring 2 or 3.
Health outcomes
At the time of the analysis (at least four years after diagnosis), 168 patients (96%) had died. Table II ].
Mean cost of chemotherapy drugs reached 4,596€, ranging from 0 to 42,705€. Mean total cost of treatment per day of hospitalisation reached 934€, ranging from 732€ to 1,715€ [ Table III ].
Other costs evaluation
The average total cost of treatment for patients with advanced or metastatic NSCLC ( CT ) reached €35,160 (n=174), ranging from €5,602 to €131,227. figure 1 .
Multivariate analysis of survival
Results obtained with final survival models using instrumental variable analysis are provided in table IV. As mentioned above, modelling the interdependence between survival and expenditures may cause endogeneity problems and biased estimates. These problems could be overcome by using instrumental variables. The accuracy of the method relies on the relevance and validity of the instrumental variables available. An instrumental variable does not itself belong in the explanatory equation (here, does not have a direct effect on survival) for identification reason and must satisfy two requirements: (i) it must be strongly (or at least not weakly) correlated with the included endogenous variable (here, expenditures) conditional on the other covariates and (ii) it cannot be correlated with the error term in the explanatory equation (Greene, [2003]; Gujarati, [2005] ). According to medical literature and to medical practice, age could be a valuable instrument in our context, and an age limit of 70 years would have clinically relevant distinctive value. Indeed, several surveys have shown that the intensity of cancer treatments is usually reduced for elderly patients (Gridelli et al., [2005] ).
These patients are generally more vulnerable to the toxicity of combined chemo-and radiation therapies, so we expected to find a negative correlation between higher age and overall treatment expenditures. In contrast, age was not expected to be a predictor of survival. Even if there is currently no elderly-specific trial (and if elderly people are under-represented in clinical trials), some published studies focusing on this topic have shown that, when all patients receive the same treatment, progression and survival rates do not differ between elderly and younger patients (Sequist and Lynch, [2003] ). Preliminary regressions of health expenditures and survival as a function of age, among other clinical variables, were ran in order to respectively assess the strength of this instrument in our empirical situation (cf. requirement 1) and whether or not the equations of interest would be identifiable.
Our results suggested that both conditions hold when using inpatient length of stay, the number of chemotherapy drugs administered, and the total cost of treatment per day of hospitalisation as proxies of health care expenditures. Indeed, age was significantly correlated to each of these variables but not with survival. Unfortunately, this was not confirmed when using outpatient health care procedures, innovative and expensive chemotherapy drugs, the number of radiotherapy sessions, and the cost of chemotherapy drugs. The instrumental technique was not applicable to these latter cases.
However, the assumption that the instrument (age) was not correlated with the error term in (Table IV) .
-Regarding the survival model as a function of the number of chemotherapy drugs administered, survival was, all other things being equal, significantly worse for patients with stage IV compared to stage IIIB disease (p=0.002), for those with past or concomitant cardiovascular disease and/or diabetes (p=0.033), and for current smokers compared to never smokers (p=0.031). Survival duration was not significantly associated with the number of chemotherapy drugs administered (Table IV) .
-Regarding the survival model as a function of total cost of treatment per day of hospitalisation, survival time was, all other things being equal, significantly shorter for patients with stage IV compared to stage IIIB (p=0.003), poor performance status (p=0.006), and past or concomitant cardiovascular and/or diabetes co-morbidities (p=0.021). Moreover, current smokers had a shorter survival than never smokers (p=0.03). Survival was also significantly shorter for patients with adenocarcinoma compared to large cell carcinoma (p=0.003), whereas this significance was only borderline for weight loss (p=0.055).
Our results also showed major differences in the significance and magnitude of parameters estimated with and without controlling for endogeneity, leading to opposite conclusions. (Table IV) .
DISCUSSION
Choice of the health care expenditure proxies
Hospitalisation is described in the literature as the most expensive cost item for advanced and metastatic NSCLC (Bordeleau, [2006] ). In Dedes et al. study, hospitalisation costs reach 68%
and 74% of the total costs of treatment in stage III and stage IV patients, respectively, versus only 14% and 26% for chemotherapy drugs (Dedes et al., [2004] ). Health care expenditures related to hospitalisation are largely integrated in our analysis, e.g. inpatient length of stay, number of outpatient health care procedures, total cost of treatment per day of hospitalisation.
Health care expenditures related to chemotherapy drugs are also detailed, e.g. number of chemotherapy drugs administered, number of expensive and innovative chemotherapy drugs administered, total cost of chemotherapy drugs). As radiotherapy can palliate the symptoms of poor-prognosis patients, the number of irradiation sessions was also taken into account (Van den Hout et al., [2006] ).
Because this is a retrospective study, rigorously assessing quality of life was not possible. The literature shows low quality of life scores in patients with locally advanced and metastatic NSCLC. Bordeleau reports a score of 0.34 (Bordeleau, [2006] (Babiak et al., [2007] ). Except for this study, the median survival reported in clinical trials was higher than in our study. It ranged from 10.5 months (Galetta et al., [2002] ) to 17.4 months (Zinner et al., [2004] ), compared to 9.6 months in this study.
The necessity to analyse the risk of endogeneity
Gravelle and Backhouse have highlighted the methodological difficulties associated with empirical investigations in health care, especially the associated endogeneity problem, and the possible time lag between expenditure and outcomes (Gravelle and Backhouse, [1987] ).
When the estimated regression equation consists of a mixture of potentially endogenous and exogenous variables, the coefficient on the endogenous variables may be biased when studies do not allow for endogeneity (Martin et al, [2008] ). The risk of endogeneity and its impact on the relationship between health care expenditures and outcome appear clearly in this study.
When endogeneity is not taken into account, the higher the total cost of treatment per day of hospitalisation, the higher the survival rate, and the higher the number of chemotherapy drugs administrated, the higher the survival rate. This would lead to the conclusion that health care expenditures have a strong positive effect on survival in patients with advanced or metastatic NSCLC, which would bias the decision-making process in favour of expensive therapies. 
Results
Implications in term of medical decision-making
Due to the short survival times observed in advanced or metastatic NSCLC, especially in the "real life situation", to the lack of consequences of health care expenditures on survival as measured by seven proxies, but also, as shown in the literature, to the significant benefit of chemotherapy on survival, the elaboration of recommendations for medical decision-making appears particularly difficult. The American Society for Clinical Oncology recommends, for example, the administration of a combination of two molecules of chemotherapy in first-line, whereas brief cyto-toxic treatments also appear optimal. Further studies encourage to maintain quality of life and to tailor therapy to patient characteristics and disease specificities 
CONCLUSION
Although there has been progress in the treatment of NSCLC, survival is still very modest for advanced and metastatic stages. In term of medical-decision making, the present study based on a "real life situation", using several proxies of health care expenditures and controlling the risk for endogeneity, encourages to limit the number of chemotherapy drugs administered and to promote the use of inexpensive drugs. This study also shows the importance of tailoring cytotoxic therapy based, according to the results of survival models, on age, stage, histology and comorbidities. Then, the focus of research on medical decision-making should be on (i) the observation of physicians' behaviour, in particular the reasons why they prescribe non efficient drugs (ii) the preservation of quality of life, based on the results of evaluations of targeted therapies which are pending in lung cancer (Bordeleau, [2006] ; Glover et al., [2004] ).
The mean estimated annual cost of targeted drugs may however reach $21,963 for Gefitinib, $31,000 for Erlotinib. As targeted cancer drugs are combined with standard regimens, the costs of these drugs add to already costly therapeutic packages. Hence, high-quality evaluations are required to provide clear information on the value and the acceptability of the Cost of hospitalisations for chemotherapy 174 10,145 (9,477) 0 -70,963 162 10,901 (9,391) 732-70,963 Total cost of chemotherapy per cure 174 1,750 (1,367) 8 -9,445 Total cost of radiotherapy 175 1,741 (3,274) 0 -22,428 76 4,008 (3,958) 491 -22427
Cost of sessions 175 1,340 (2,076) 0 -9,695 76 3,085 (2,131) 
-9695
Cost of hospitalisations for radiotherapy 175 401 (2,219) 0 -19,753 10 7,023 (6,600) 732 -19752 
